A Simple and Computationally Efficient Approach to Multifactor Dimensionality Reduction Analysis of Gene-Gene Interactions for Quantitative Traits

Jiang Gui1,2, Jason H. Moore1,2,3, Scott M. Williams1,3, Peter Andrews1, Hans L. Hillege4, Pim van der Harst5, Gerjan Navis5, Wiek H. Van Gilst4, Folkert W. Asselbergs6, Diane Gilbert-Diamond1,2

1 Institute for Quantitative Biomedical Sciences, Geisel School of Medicine, Lebanon, New Hampshire, United States of America, 2 Section of Biostatistics and Epidemiology, Departments of Community and Family Medicine, Geisel School of Medicine, Lebanon, New Hampshire, United States of America, 3 Department of Genetics, Geisel School of Medicine, Lebanon, New Hampshire, United States of America, 4 Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands, 5 Department of Nephrology, University Medical Center Groningen, Groningen, The Netherlands, 6 Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands

Abstract

We present an extension of the two-class multifactor dimensionality reduction (MDR) algorithm that enables detection and characterization of epistatic SNP-SNP interactions in the context of a quantitative trait. The proposed Quantitative MDR (QMDR) method handles continuous data by modifying MDR’s constructive induction algorithm to use a T-test. QMDR replaces the balanced accuracy metric with a T-test statistic as the score to determine the best interaction model. We used a simulation to identify the empirical distribution of QMDR’s testing score. We then applied QMDR to genetic data from the ongoing prospective Prevention of Renal and Vascular End-Stage Disease (PREVEND) study.

Introduction

The view that the genetic basis of common human diseases can be explained by sequence variation in a few genetic loci has been recently replaced by a new appreciation for the complexity of biological networks and the interplay between proteins that jointly influence phenotypes [1]. The recent advances in high-throughput genotyping techniques have made large quantities of genotype data commonplace in genetic epidemiology studies and therefore have enabled researchers to interrogate the entire genome. Researchers have extensively analyzed single SNP effects for a wide variety of diseases/phenotypes with variable results, but in most cases with a large proportion of the genetic component (heritability) left unexplained. It has been proposed that these limitations are due to the analytical strategy that limits analyses to only single SNPs [2], and it is therefore becoming more commonplace to assess the challenge of identifying SNP-SNP interactions.

The problem of identifying interactive SNP effects in a case-control study, which can be formulated as predicting binary outcomes, has been studied extensively and has demonstrated great promise in recent years [3–5]. Multifactor Dimensionality Reduction MDR was developed as a nonparametric and model-free data mining method for detecting, characterizing, and interpreting epistasis in the absence of significant main effects in genetic and epidemiologic studies of complex traits such as disease susceptibility [3]. The goal of MDR is to change the representation of the data using a constructive induction algorithm to make non-additive interactions easier to detect using a classification method such as naive Bayes or logistic regression. Comparative studies [6,7] that use extensive simulations show that MDR has the best performance when the true multi-SNP effects are non-additive [2,3,7–12].

Despite the fact that MDR has been extended to various settings [13–17], there have been few attempts to develop methods that systematically identify SNP-SNP interactions in relation to quantitative outcomes such as body mass index, tumor size and survival time. Because in many cases, analyzing phenotypes as continuous rather than binary outcomes can be more powerful due to large variability in the outcome distribution it is important to develop methods that permit the analyses of continuous traits.

Many methods including Combinatorial Partitioning Method (CPM) [18], Repeated Partitioning Method (RPM) [19] and U-statistics [20] were developed to identify interactions for quantitative traits. CPM and RPM are both computationally intensive and the U-statistics approach is limited to detecting interaction models with main effects. In 2006, Generalized MDR (G-MDR) [17] was proposed to extend the MDR algorithm to be applicable to continuous phenotypes and allow covariate adjustment. In 2011, Model based MDR (MB-MDR) [21] was developed to
improve MDR using parametric regression; this method can also be applied to continuous outcomes. However, neither G-MDR nor MB-MDR provides a computationally efficient algorithm that is easy to implement. MB-MDR is implemented in R (http://www.r-project.org/) but it can only search over all one-way and two-way interaction models. G-MDR still requires a dichotomous outcome in the data file. Furthermore, the success rate of each algorithm on continuous outcomes was not evaluated using simulations.

In the current paper, we present an extension of the multifactor dimensionality reduction (MDR) algorithm to detect and characterize epistatic interactions in the context of a quantitative outcome (QMDR). We first present the type-I error and success rate of the proposed method using simulated datasets under different epistasis models. We then present the results of QMDR applied to genetic data from the ongoing prospective Prevention of Renal and Vascular End-Stage Disease (PREVEND) study.

### Materials and Methods

In this section, we introduce T statistics and describe how they can be used in the MDR framework in the context of quantitative outcomes.

#### MDR Algorithm

Traditional MDR is a data reduction approach that identifies multi-locus combinations of genotypes that are associated with either high or low risk of disease and uses them to define a new single high/low risk attribute. The general process of defining a new attribute as a function of two or more other attributes is referred to as constructive induction or attribute construction [22]. Constructive induction using MDR for binary outcomes (e.g. case-control status) is accomplished in the following way:

1. Assume there are m SNPs in the dataset; in order to examine a K-order interaction, select K SNPs from the m SNPs.

---

**Figure 1. Empirical distribution of the 10-fold cross-validated testing score.** The three curves on each figure represent the testing score from 2-way, 3-way and 4-way models. 
doi:10.1371/journal.pone.0066545.g001
2. Construct a contingency table using these K SNPs and calculate case-control ratios for each multi-locus genotype.

3. Let R be the ratio of cases to controls in the whole dataset. For each multi-locus genotype, if the ratio of cases to controls exceeds T, it is considered high-risk. Otherwise, it is considered low-risk. Once all genotypes are labeled 'high-risk' and 'low-risk', a new binary attribute is created constructed by pooling the “high-risk” genotype combinations into one group and the “low-risk” into another group.

MDR uses a simple probabilistic classifier that is similar to a naive Bayes classifier [9] to model the relationship between variables constructed using MDR and case-control status. Naive Bayes classifiers were assessed using balanced accuracy [23]. Balanced accuracy is defined as the arithmetic mean of sensitivity and specificity:

$$\frac{1}{2} \left( \frac{TP}{(TP + FN)} + \frac{TN}{(TN + FP)} \right) = \frac{(sensitivity + specificity)}{2}$$ (1)

where TP are true positives, TN are true negatives, FP are false positives, and FN are false negatives. For each dataset, MDR evaluates all possible K-way interactions and identifies the best model using balanced accuracy. To determine the K loci that give the best model overall, MDR uses ten-fold cross-validation:

1. Divide the dataset into 10 partitions. Using 9/10 of the data as a training set and the rest as a testing set.
2. Compute the training balanced accuracy for each K-way interaction in the training set.
3. Using the K-way model that has the best training balanced accuracy, predict the case-control status in the testing set.
4. Repeat steps two-three 10 times so that each partition is included in the testing set once.
5. Compute a testing balanced accuracy by using the case-control predictions and actual case-control status for all 10 testing sets. For the K-way models that are chosen from the training sets, record how many times each is identified as the best model (cross-validation consistency).

The best MDR model is selected as that with the maximum testing balanced accuracy and highest cross-validation consistency. The latter is used as a tie-break. If both statistics are tied, then the more parsimonious model is chosen as the overall best model.

Quantitative MDR Algorithm

Quantitative MDR (QMDR) extends the MDR algorithm described above to work with quantitative or continuous phenotypes. Instead of comparing the case-control ratio of each multi-locus genotype to a fixed threshold R, we propose to compare the mean value of each multi-locus genotype to the overall mean. Constructive induction by QMDR is done as follows:

1. Assume there are m SNPs in the dataset; in order to examine a K-order interaction, select K SNPs from the m SNPs.
2. For each multi-locus genotype combination defined by the K SNPs, calculate the mean value and compare it with the overall mean.
3. If the mean value from the genotype combination is larger than the overall mean, the corresponding genotype is considered high-level. Otherwise, it is considered low-level. Once all of the genotypes are labeled ‘high-level’ and ‘low-level’, a new binary attribute is created by pooling the “high-level” genotype combinations into one group and the “low-level” into another group.

With quantitative outcomes, we cannot use balanced accuracy to characterize the relationship between the QMDR attribute and phenotype. Instead, we compare the outcome between high and low level groups defined by the QMDR attribute using a T-test and then use the T-statistic as a training score to choose the best model. The cross-validation procedure for QMDR is the same as that used in traditional MDR. The difference is that we define the training score and testing score from the T-test (replacing the training and testing balanced accuracy). We use the training score to determine the best K-order interaction model and use the maximum testing score to identify the best overall model. When there is no SNP effect, QMDR attributes from the testing set are equivalent to ones randomly assigned to the high or low level group. Therefore we expect that the null distribution of the testing score follows a normal distribution with mean 0. We can then use an empirical null distribution to estimate the p-value of the chosen model. In the next section, we will use simulated data to compare empirical p-value and the permuted p-value to verify the above hypothesis.

Simulations

To demonstrate the strength of the proposed method, we designed two simulations: Simulation I focused on estimating the threshold for 5% type I error using a quantitative outcome and SNPs that are independent of each other. Simulation II aimed at estimating the success rate of our proposed QMDR with a quantitative outcome and two functional interacting SNPs embedded within a set of 18 independent SNPs.

Simulation I. The goal of simulation I was to study the testing score’s null distribution. To this end, we let the SNP number m = {10, 20, 50} and the sample size n = {200, 400, 800, 1600}. For each combination of m and n, we simulated m SNPs with a minor allele frequency drawn from a uniform distribution over the interval (0.1, 0.5) using Bernoulli distribution. We then simulated n continuous outcomes from a standard normal distribution. We simulated the SNP data and outcomes independently of each other so that there is no association between SNPs and outcome. We repeated this to create 2000 null datasets for each m by n combination. Thus, we created 24,000 total datasets. All simulations were carried out in R (http://cran.r-project.org/). We ran QMDR for each dataset and searched over all 1–4 way interactions. The testing score was obtained using a 10-fold cross-validation.

Simulation II. The goal of simulation II was to study the success rate of the proposed method. We also compared QMDR with the original MDR algorithm and GMMDR to demonstrate the success rate gained by using the continuous outcome.

We first generated datasets based on different penetrance functions. We previously developed a total of 70 different penetrance functions that define a probabilistic relationship between the outcome and SNPs where the outcome is dependent on genotypes from two loci in the absence of any marginal effects [23]. These purely epistatic models were distributed evenly across seven broad-sense heritabilities (0.01, 0.02, 0.05, 0.1, 0.2, 0.3, and 0.4) and two different minor allele frequencies (0.2 and 0.4) using Bernoulli distribution, where all functional SNPs in the data set had either one or the other minor allele frequencies. A total of five models for each of the 14 heritability-allele frequency combinations were generated for a total of 70 models. We also vary the sample size to include sample size n = {400, 800, 1600}. Since the
original outcome is case-control status and the penetrance function
denotes the probability of being a case for each genotype
combination, we make the following change to simulate contin-
uous outcome using the same penetrance functions:

Let \(f_{ij}\) be the element from the \(i^{th}\) row and \(j^{th}\) column of a
penetrance function, and are the two functional interacting SNPs.
The Quantitative outcome was simulated from a normal
distribution

\[
y|\text{SNP1} = i, \text{SNP2} = j \sim N(f_{ij}, 1)
\]

We repeated 100 times to get 100 datasets for each model.

**Real Data Analysis**

The sample analyzed in this study was obtained from the
ongoing prospective Prevention of Renal and Vascular End-Stage
Disease (PREVEND) study [24]. The PREVEND study was
designed to prospectively investigate the natural course of
albuminuria and its relation to renal and cardiovascular disease
in a large cohort drawn from the general population. Details of
the study protocol have been described previously [25, 26]. In
summary, during 1997–1998, all 85,421 inhabitants of the city
of Groningen, the Netherlands, from the ages of 28 to 75 years old,
were sent a one-page postal questionnaire. After exclusion of
subjects with type 1 diabetes mellitus, females who were possibly
pregnant, and males and females not able or willing to participate,
a total of 6,000 subjects with a urinary albumin concentra-
tion \(\geq 10\ mg\ l^{-1}\) and a random control sample of subjects with a
urinary albumin concentration \(< 10\ mg\ l^{-1}\) \((n = 2592)\ completed
the screening protocol and formed the baseline PREVEND cohort
\((n = 8592)\). From this cohort, we selected a random sample of 2527
subjects (1338 females and 1189 males) as being representative of
the entire population from which the PREVEND cohort was
selected. These individuals were used in the present study to
explore genetic predictors of tissue plasminogen activator (t-PA)

---

**Figure 2. Empirical distribution of the 10-fold cross-validated testing score.** The three curves on each figure represent testing scores from datasets with 10, 20, and 50 SNPs.
doi:10.1371/journal.pone.0066545.g002
and plasminogen activator inhibitor-1 (PAI-1) levels in the general population. We examined 7 polymorphisms from the renin-angiotensin, bradykinin and fibrinolytic systems that have been previously reported [24].

We carried out analysis in females and males separately since the distributions of t-PA and PAI-1 are gender specific. For each gender and expression combination, we first used an ANOVA and F-test to identify the main effect of each polymorphism. We filtered out the significant main effects via a two-step procedure: First, we fit a linear regression with PAI-1 or tPA plasma concentrations and all of the SNPs with a significant main effect (p<0.05). Secondly, we applied QMDR using the residual as the new quantitative trait to search over all possible two-way, three-way and four-way interactions. We used 10-fold cross-validation to determine the best overall model. We then ran a 10,000-fold permutation testing to estimate the p-value of the chosen model. Finally we compared the p-value obtained through permutation testing with that estimated using the empirical scores from simulation I.

### Results

#### Simulation I Results

The testing scores were expected to follow a standard normal distribution, since when the sample size is large (n >50), the T-statistics are asymptotically standard normal. However, from figure 1, the empirical distributions were not exactly standard normal. The estimated standard deviation was 1.6 with a slight right skew. We believe that this deviation was due to extra variation in the cross-validation procedure that resulted from the overlap among the training sets.

On the other hand, as seen in figure 1 and 2, we can tell that the null distributions are similar across different sample sizes, number of SNPs and interaction orders. The right tail regions, in particular, show almost perfect overlap. This indicates that we can use the 95th quantile of the empirical distribution as a threshold to eliminate weak QMDR models, which is exactly what permutation testing can offer. Since the null distributions are “invariant”, we can potentially save a lot of computing time by comparing the testing score with a pre-calculated empirical distribution. In table 1, we used the 95th quantile of datasets with and plasminogen activator inhibitor-1 (PAI-1) levels in the general population. We examined 7 polymorphisms from the renin-angiotensin, bradykinin and fibrinolytic systems that have been previously reported [24].

We carried out analysis in females and males separately since the distributions of t-PA and PAI-1 are gender specific. For each gender and expression combination, we first used an ANOVA and F-test to identify the main effect of each polymorphism. We filtered out the significant main effects via a two-step procedure: First, we fit a linear regression with PAI-1 or tPA plasma concentrations and all of the SNPs with a significant main effect (p<0.05). Secondly, we applied QMDR using the residual as the new quantitative trait to search over all possible two-way, three-way and four-way interactions. We used 10-fold cross-validation to determine the best overall model. We then ran a 10,000-fold permutation testing to estimate the p-value of the chosen model. Finally we compared the p-value obtained through permutation testing with that estimated using the empirical scores from simulation I.

#### Real Data Results

The ANOVA for PAI-1 revealed a significant main effect from PAI 4G/5G with F-test p-value of 0.0006 for female and 0.002 for male. This verified previous findings [24,27]. For tPA, we found a significant main effect of ATR1AC in females only (p = 0.04) and none in males.

After adjusting out the main effect of PAI 4G/5G and ATR1AC using residuals, we ran QMDR to identify interaction models. In table 3, we list the best interaction models identified from 10-fold cross-validation for PAI-1 and tPA expression in males and females. The best model for PAI-1 in females is a four-way interaction of BR2_58CT, ATR1AC, ACEID and BRB2EX1. The 10,000 permutation testing revealed a significant p-value of 0.014. Since we also found a significant main effect of PAI 4G/5G, we ran a linear regression model with PAI 4G/5G and an interaction between BR2_58CT, ATR1AC, ACEID and BRB2EX1.
BRB2EX1 as the predictors and found that those 5 SNPs could explain 9.5% of the total variance of PAI-1 in females. Considering the sample size (>1000) and the continuous outcome, this indicated a strong association between PAI-1 and the 5 SNPs in females. The best interaction models from the other 3 datasets were not significant as determined by the permutation testing. One interesting thing to note was that removing the main effect did not exclude it from being chosen in the best interaction model. For example, PAI 4G/5G’s main effect was removed from PAI-1 in males and the best interaction model is four-way interactions of PAI 4G/5G, BR2_58CT, ACEID and BRB2EX1. We note that the amount of variance explained by the significant model was much better than previously reported using other analytical methods.

The empirical p-values were very close (difference less than 2%) to those obtained from permutation tests. For p-values that are within the critical region, the empirical p-values are more accurate (1.4% vs 1.8%). This suggests that we can rely on the empirical distribution from simulations to estimate the significance of QMDR models, potentially saving months of computation time in genome-wide association studies.

### Discussion

In this paper, we presented a novel algorithm to identify SNP interactions associated with a quantitative outcome. There are two unique contributions from this paper: first of all, we offer a computationally efficient algorithm, QMDR, to identify epistatic models that are associated with a quantitative outcome. We have distributed free Java-based software for this QMDR on sourceforge.net. Secondly, we present a testing score that is “invariant” for all sample sizes, number of SNPs and interaction orders. Simulations and real data analyses both showed that the empirical p-value is very close to permuted p-value thereby permitting a significant reduction in computing time.

QMDR changes the representation of the data by pooling different genotype combinations into a two-level single attribute. This challenges the traditional analysis method of using many dummy variables to represent every genotype combination. Due to limitations in sample size, some of the dummy variables used in traditional models can be represented by very sparse or no data. This makes the modelling of high-order combinations very difficult. QMDR solves this dilemma elegantly by collapsing all high-level genotypes and all low-level genotypes into a two level attribute. This not only makes it easier to detect higher order interaction terms, but also makes it possible to incorporate the QMDR attribute into other statistical and machine learning algorithms, such as Boosting [28] and neural networks. This will allow researchers to build more accurate models that involve multiple genotype combinations. As we can see from real data results, QMDR successfully identifies a four-way interaction model that is strongly associated with female PAI-1 levels. This is good example of how QMDR can gain biological information above that previously obtained using a more traditional ANOVA approach [24].

QMDR also offers a cross-validation procedure to pick the best model based on the testing score. Since high-order interactions tend to have better training scores than low-order interactions, these cross-validation procedures are necessary to limit model over-fitting. The QMDR algorithm also explores the empirical distribution of the testing score from the null models and applies it to estimate the significance of the selected model. From the simulation, we demonstrated that QMDR can detect the presence of multiplicative interaction models, even when main effects are not statistically significant. These epistatic combinations tend to be missed or dropped when using traditional linear regression approaches. Last but not least, QMDR is computationally efficient. One of the first algorithms developed to explore gene-gene interactions was the Combinatorial Partitioning Method (CPM) [18]. While elegant, CPM’s functionality is limited by its inefficiency; its computing time increase exponentially with the number of genes examined (0(2^p)). In contrast, QMDR’s computing time is 0(p^3) for two-way interactions. QMDR is has a nearly two-fold computational speed advantage over GMDR, as demonstrated through simulations. This increase in speed is vitally important and makes QMDR a feasible method to use when exploring large datasets such as genome-wide association studies.

Despite the advantages stated above, one limitation to the approach is that the QMDR method does not have a way to adjust for covariate effects such as age, gender and smoking status, an often necessary step to obtain an unconfounded SNP interactions-outcome association. Investigators can, however, first fit a model with potential confounders and the outcome of interest and then use the residuals in QMDR, as we did to adjust for SNP main effects in this paper. However, if there are too many covariates, this approach may overfit the data and sometimes fail due to limited sample size. One strength of QMDR is that it can be extended to the analysis of interactions among non-genetic variables as well as gene-environment interactions. For example, QMDR will facilitate pharmacogenomic analyses by identifying combinations of drug treatments and genotypes that affect time to progression.

In summary, we demonstrate that QMDR is a promising dimension reduction method for the efficient identification of SNP interactions. We believe that it will play an important role as part of a research strategy to understand genetic influences on disease outcomes that embraces the complexity of the genotype-phenotype mapping relationship.

We have uploaded Java-based QMDR software as part of MDR 3.0 to: http://sourceforge.net/projects/mdr/.
Acknowledgments
We would like to thank Ms. Xiaofei He and Ms. Crystal Flaherty for their careful proof-reading.

Author Contributions
Conceived and designed the experiments: JHM. Wrote the paper: JG. Analyzed the simulated data and real data: JG. Edited the discussion sections of the manuscript: JHM FWA. Contributed materials and edited the simulation section: SMW. Developed a Java version of the proposed method, analyzed the simulation data: PA. Contributed materials in real data: HLH PvdH GN WHVG FWA. Edited the Introduction, simulation, and results sections of the manuscript: DG-D.

References
1. Manolio TA (2009) Cohort studies and the genetics of complex disease. Nat Genet 41: 5–6.
2. Moore JH, Williams SM (2009) Epistasis and its implications for personal genetics. Am J Hum Genet 85: 309.
3. Ritchie MD, Hahn LW, Roold N, Bailey LR, Dupont WD, et al. (2001) Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69: 130–147. 10.1086/321276.
4. Park MY, Hastie T (2008) Penalized logistic regression for detecting gene interactions. Biostatistics 9: 50–60.
5. Huang J, Lin A, Narasimhan B, Quertemous T, Huang CA, et al. (2004) Tree-structured supervised learning and the genetics of hypertension. Proc Natl Acad Sci U S A 101: 10529–10534.
6. He H, Oetting W, Brott M, Basu S (2009) Power of multifactor dimensionality reduction for detecting gene-gene interaction in a case-control study. BMC medical genetics 10: 127.
7. Ritchie MD, Hahn LW, Moore JH (2003) Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 24: 150–157.
8. Hahn LW, Moore JH (2004) Ideal discrimination of discrete clinical endpoints using multifactor genotypes. In Silico Biol 4: 183–194.
9. Moore JH (2007) Genome-wide associations and computational strategies for detecting gene-gene interactions. J Theor Biol 241: 252–261. 10.1016/j.jtbi.2005.11.036.
10. Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, et al. (2006) A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 241: 252–261. 10.1016/j.jtbi.2005.11.036.
11. Moore JH (2007) Genomewide analysis of epistasis using multifactor dimensionality reduction: Feature selection and construction in knowledge discovery. Knowledge Discovery and Data Mining: Challenges and Realities: 17.
12. Moore JH, Asselbergs FW, Williams SM (2010) Bioinformatics challenges for genome-wide association studies. Bioinformatics 26: 445–455.
13. Gui J, Andrew AS, Andrews P, Nelson HM, Kelley KT, et al. (2011) A robust multifactor dimensionality reduction method for detecting gene-gene interactions with application to the genetic analysis of bladder cancer susceptibility. Ann Hum Genet 75: 20–28. 10.1111/j.1469-1809.2010.00624.x; 10.1111/j.1469–1809.2010.00624.x.
14. Gui J, Andrew AS, Andrews P, Nelson HM, Kelley KT, et al. (2010) A simple and computationally efficient sampling approach to covariate adjustment for multifactor dimensionality reduction analysis of epistasis. Hum Hered 70: 219–225. 10.1159/000319175.
15. Gui J, Moore JH, Kelney KT, Maniotis CJ, Karagas MR, et al. (2011) A novel survival multifactor dimensionality reduction method for detecting gene-gene interactions with application to bladder cancer prognosis. Hum Genet 129: 101–110. 10.1007/s00439–010–0905–9.
16. Chong Y, Lee SY, Elston RC, Park T (2007) Odds ratio based multifactor-dimensionality reduction method for detecting gene–gene interactions. Bioinformatics 23: 71–76.
17. Lou XY, Chen GB, Yan L, Ma JZ, Zha J, et al. (2007) A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. The American Journal of Human Genetics 80: 1123–1137.
18. Nelson M, Kardia S, Ferrell R, Sing C (2001) A combinatorial partitioning method to identify multifactorial genetic patterns that predict quantitative trait variation. Genome Res 11: 450–470.
19. Culverhouse R, Klein T, Shannon W (2004) Detecting epistatic interactions contributing to quantitative traits. Genet Epidemiol 27: 141–152.
20. Li M, Ye C, Fu W, Elston RC, Lu Q (2011) Detecting genetic interactions for quantitative traits with U-statistics. Genet Epidemiol 35: 457–468.
21. Calle ML, Urrea V, Malats i Riera N, Van Steen K (2008) MB-MDR: Model-based multifactor dimensionality reduction for detecting interactions in high-dimensional genomic data.
22. Michalski RS (1983) A theory and methodology of inductive learning. Artif Intell 20: 111–161.
23. Velez DR, White BC, Motsinger AA, Bush WS, Ritchie MD, et al. (2007) A balanced accuracy function for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction. Genet Epidemiol 31: 306–315. 10.1002/gepi.20211.
24. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, et al. (2007) Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics 89: 362–369.
25. Hillege HL, Faller V, Diercks GFH, van Gilst WH, de Zeeuw D, et al. (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777–1782.
26. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, et al. (2006) The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. THROMBOSIS AND HAEMOSTASIS-STUTTGART- 96: 471.
27. Margaglione M, Cappucci G, d'Addedda M, Colaizzo D, Giuliani N, et al. (2008) Association of estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69: 138–150.
28. Freund Y, Schapire R (1995) A decision-theoretic generalization of on-line learning and an application to boosting: 23–37.